{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sinha R"],"funding":["NCATS NIH HHS","NIAAA NIH HHS"],"pagination":["e13116"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9872962"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(2)"],"pubmed_abstract":["Chronic alcohol use increases risk of alcohol withdrawal symptoms (AW) and disrupts stress biology and resilient coping, thereby promoting excessive alcohol intake. Chronic alcohol intake and multiple alcohol detoxifications are known to impair brain medial prefrontal cortex (mPFC) and striatal functioning, regions involved in regulating stress, craving and alcohol intake. In two related studies, we examined whether AW predicts this functional brain pathology and whether Prazosin versus Placebo treatment may reverse these effects. In Study 1, patients with Alcohol Use Disorder (AUD) (N = 45) with varying AW levels at treatment entry were assessed to examine AW effects on corticostriatal responses to stress, alcohol cue and neutral visual images with functional magnetic resonance imaging (f"],"journal":["Addiction biology"],"pubmed_title":["Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder."],"pmcid":["PMC9872962"],"funding_grant_id":["R01 AA029113","R01 AA013892","TL1 TR000125","R01 AA020504"],"pubmed_authors":["Seo D","Sinha R","Wemm S","Fogelman N","Angarita G","Hermes G"],"additional_accession":[]},"is_claimable":false,"name":"Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder.","description":"Chronic alcohol use increases risk of alcohol withdrawal symptoms (AW) and disrupts stress biology and resilient coping, thereby promoting excessive alcohol intake. Chronic alcohol intake and multiple alcohol detoxifications are known to impair brain medial prefrontal cortex (mPFC) and striatal functioning, regions involved in regulating stress, craving and alcohol intake. In two related studies, we examined whether AW predicts this functional brain pathology and whether Prazosin versus Placebo treatment may reverse these effects. In Study 1, patients with Alcohol Use Disorder (AUD) (N = 45) with varying AW levels at treatment entry were assessed to examine AW effects on corticostriatal responses to stress, alcohol cue and neutral visual images with functional magnetic resonance imaging (f","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-03-27T16:49:04.74Z","creation":"2025-04-19T14:30:12.541Z"},"accession":"S-EPMC9872962","cross_references":{"pubmed":["34856641"],"doi":["10.1111/adb.13116"]}}